In a recent Industry Insight interview with Technology Networks, Dr. Graeme Daniels, discusses how advanced droplet-based microfluidic systems like Cyto-Mine® Chroma are reshaping workflows in biotherapeutic development.

By enabling multiplexed single-cell assays, this next-gen platform helps biopharma companies streamline clone selection and functional screening, significantly reducing development timelines.

Cyto-Mine® Chroma builds on the existing Cyto-Mine® system by offering expanded multiplexing and laser detection capabilities. This innovation empowers researchers to simultaneously ask complex biological questions – such as secretion profiling, viability, and manufacturability – earlier in the pipeline, ultimately enhancing productivity and accelerating therapeutic development.

For more insights on the latest developments in biologics and cell line research, visit Sphere Bio’s Knowledge Hub or or dive into our Cyto-Mine® Chroma solution for early-stage screening.

This article is part of our Editorial Coverage series, showcasing Sphere Bio’s thought leadership and technological contributions in top-tier industry publications. Stay tuned for more.